Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy
Bryostatin 1 is a unique therapeutic lead, however its scarce natural sources have hampered its use in treatment of human disease. Here, the authors use a scalable synthesis of bryostatin 1 to make close-in analogs which potently induce increased cell surface expression holding potential for immunot...
Guardado en:
Autores principales: | Clayton Hardman, Stephen Ho, Akira Shimizu, Quang Luu-Nguyen, Jack L. Sloane, Mohamed S. A. Soliman, Matthew D. Marsden, Jerome A. Zack, Paul A. Wender |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ebe37911de374c93a36c1ee604f378a0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
por: Hsin-Yu Liu, et al.
Publicado: (2021) -
Overexpressed PKCδ downregulates the expression of PKCα in B16F10 melanoma: induction of apoptosis by PKCδ via ceramide generation.
por: Kuntal Halder, et al.
Publicado: (2014) -
miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma
por: Mai-Huong Thi Nguyen, et al.
Publicado: (2021) -
Essential Role Of High Glucose-Induced Overexpression Of PKCβ And PKCδ In GLP-1 Resistance In Rodent Cardiomyocytes
por: Pan X, et al.
Publicado: (2019) -
Aldosterone rapidly activates p-PKC delta and GPR30 but suppresses p-PKC epsilon protein levels in rat kidney
por: Eiam-Ong Somchit, et al.
Publicado: (2019)